Tricin as a potential enhancer for the treatment of cisplatin-based skin cancer
Tricin as a potential enhancer for the treatment of cisplatin-based skin cancer https://www.tauli.cat/institut/wp-content/uploads/2020/06/1593154770_tmp_IMG_1783-e1593155055158.jpg 585 409 Guillem Cebrian https://www.tauli.cat/institut/wp-content/uploads/2020/02/IMG-1030-150x150.pngAt the end of December 2019, we talked about the effectiveness of trichina as an adjuvant of cisplatin in treatment. Squamous cell carcinoma is the second most common type of skin cancer. It causes the abnormal growth of squamous cells in the epidermis and represents 20-25% of all skin cancers in Spain. This study led by an I3PT team, led by Sílvia Gil, in close collaboration with…
READ MORE